Advertisement

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Jorge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf, Dong-Wook Kim, Anna G. Turkina, Zhi-Xiang Shen, Ricardo Pasquini, H. Jean Khoury, Steven Arkin, Angela Volkert, Nadine Besson, Richat Abbas, Junyuan Wang, Eric Leip and Carlo Gambacorti-Passerini
This article has an Erratum 122(14):2524

Article Information

Citation 
vol. 118 no. 17 4567-4576
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted May 25, 2011
  • Accepted August 10, 2011
  • Published online October 27, 2011.

Article Versions


Contributors 
  • Jorge E. Cortes, 1M. D. Anderson Cancer Center, Houston, TX;
  • Hagop M. Kantarjian, 1M. D. Anderson Cancer Center, Houston, TX;
  • Tim H. Brümmendorf, 2Universitäts-Klinikum Aachen, RWTH Aachen, Germany; 3Universitäts-Klinikum Hamburg-Eppendorf, Hamburg, Germany;
  • Dong-Wook Kim, 4Seoul St Mary's Hospital, Seoul, South Korea;
  • Anna G. Turkina, 5Hematology Research Center, Moscow, Russia;
  • Zhi-Xiang Shen, 6Ruijin Hospital, Shanghai, China;
  • Ricardo Pasquini, 7Hospital das Clínicas da Universidade Federal do Paraná, Paraná, Brazil;
  • H. Jean Khoury, 8Winship Cancer Institute of Emory University, Atlanta, GA;
  • Steven Arkin, 9Pfizer Inc, Cambridge, MA;
  • Angela Volkert, 9Pfizer Inc, Cambridge, MA;
  • Nadine Besson, 10Pfizer Global Research and Development, Paris, France;
  • Richat Abbas, 11Pfizer Inc, Collegeville, PA; and
  • Junyuan Wang, 9Pfizer Inc, Cambridge, MA;
  • Eric Leip, 11Pfizer Inc, Collegeville, PA; and
  • Carlo Gambacorti-Passerini, 12University Milano Bicocca, Monza, Italy

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output